Swedish biopharma company BioArctic AB has announced its partnership with AAX Biotech, a biotech company specializing in next-generation antibody therapeutics. BioArctic will utilize AAX Biotech’s proprietary epitope mapping technology, Seqitope™, to improve the development of antibody-based medicines for neurodegenerative diseases.
AAX Biotech’s Seqitope™ is a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. This technology represents a significant milestone for AAX Biotech, highlighting the company’s role in advancing research and contributing to the fight against neurodegenerative diseases that affect millions of people worldwide.
“Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases,” says Maria L. Knudsen, CEO of AAX Biotech. “We are fully committed to this challenging project and are eager to apply our technology to support BioArctic.”
For more information about this partnership or about AAX Biotech’s Seqitope™ technology, please contact Maria Lisa Knudsen at [maria.knudsen@aaxbiotech.com](mailto:maria.knudsen@aaxbiotech.com) or visit [www.aaxbiotech.com](http://www.aaxbiotech.com).
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/5TP3LYI5GFDFFCY33GYY2YYDWE.jpeg)
